Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for patients with serious diseases. The company operates through a diversified portfolio spanning ophthalmology, immunology and inflammation, oncology,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Regeneron Pharmaceuticals does
In the company’s own words
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for patients with serious diseases. The company operates through a diversified portfolio spanning ophthalmology, immunology and inflammation, oncology, hematology, cardiovascular and metabolic diseases, neurology, and rare diseases. Regeneron's website is www.regeneron.com.
The company's marketed products include EYLEA and EYLEA HD for retinal diseases, Dupixent for allergic and inflammatory conditions, Libtayo for various cancers, Praluent for cardiovascular risk reduction, Kevzara for rheumatoid arthritis, and numerous other approved therapeutics. In 2025, Regeneron reported total revenues of approximately $14.3 billion with net income of $4.5 billion. The company maintains a robust pipeline of product candidates in clinical development across multiple therapeutic areas, with several programs in Phase 2 and Phase 3 trials.
Regeneron's core competitive advantages stem from its proprietary technology platforms, particularly VelociSuite, which encompasses VelocImmune, VelociGene, VelociMouse, VelociMab, and related technologies for discovering and developing fully human antibodies and bispecific antibodies. The company also operates the Regeneron Genetics Center, a subsidiary leveraging de-identified genomic and clinical data from over three million sequenced samples to identify novel therapeutic targets and validate genetic associations.
The company maintains significant strategic collaborations with major pharmaceutical partners. Sanofi collaborates on the global development and commercialization of Dupixent, Kevzara, and itepekimab, while Bayer partners on EYLEA development and commercialization outside the United States. Regeneron also collaborates with Alnylam Pharmaceuticals on RNAi therapeutics and with Intellia Therapeutics on CRISPR/Cas9 gene-editing technology.
Regeneron operates as an accelerated filer with the Securities and Exchange Commission and maintains manufacturing and commercial capabilities alongside its research and development operations. The company's business model emphasizes maintaining a strong scientific research foundation while building integrated clinical development, manufacturing, and commercial capabilities to advance innovative medicines to patients globally.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- TARRYTOWN, NY
- Fiscal year end
- December
- CIK
- 872589
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Regeneron Pharmaceuticals — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Regeneron Pharmaceuticals’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Regeneron Pharmaceuticals’s bonds, as funds hold them
Funds report holding 2 issues of Regeneron Pharmaceuticals’s debt, $257.23M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.04%, maturing 2030 to 2050.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Regeneron Pharmaceuticals and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Regeneron Pharmaceuticals's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Regeneron Pharmaceuticals's last four quarterly filings that the numbers alone won't show?”